X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Sun Pharma will gain access to Taro's pipelines, including Diamox (acetazolamide), an carbonic anhydrase inhibitor used for treating edema due to congestive heart failure in patients.
Lead Product(s): Acetazolamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Diamox
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Taro Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger June 24, 2024
Details:
Under the terms of this agreement, Takeda has granted Sun Pharma non-exclusive patent licensing rights for the commercialization of Voltapraz (vonoprazan) in India.
Lead Product(s): Vonoprazan Fumarate
Therapeutic Area: Gastroenterology Product Name: Voltapraz
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 21, 2024
Details:
MM-II is a novel non-opioid intra-articular injection for treating osteoarthritis knee pain. It leverages multilamellar liposomes to reduce joint friction and wear, providing sustainable pain relief.
Lead Product(s): MM-II
Therapeutic Area: Musculoskeletal Product Name: MM-II
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Moebius Medical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2024
Details:
Announced the filing of a marketing authorisation application with the European Medicines Agency for Nidlegy, an investigational neoadjuvant therapy, for locally advanced, fully resectable melanoma.
Lead Product(s): L19IL2,L19TNF
Therapeutic Area: Oncology Product Name: Nidlegy
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Philogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2024
Details:
Sun Pharma will gain access to Taro's pipelines, including Diamox (acetazolamide), an carbonic anhydrase inhibitor used for treating edema due to congestive heart failure in patients.
Lead Product(s): Acetazolamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Diamox
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Taro Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger May 23, 2024
Details:
Winlevi (clascoterone) cream is an androgen receptor inhibitor, recently received approval form the TGA to commercilize in the australian market. It is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Lead Product(s): Clascoterone
Therapeutic Area: Dermatology Product Name: Winlevi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
Through this merger, Sun Pharma will gain access to Taro's pipelines, enabling further commercialization in the market, including Diamox (acetazolamide), an carbonic anhydrase inhibitor used for treating edema due to congestive heart failure in patients.
Lead Product(s): Acetazolamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Diamox
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Taro Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger January 17, 2024
Details:
The financing will be used to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems, including LYN-005 (risperidone), being developed for schizophrenia and bipolar I disorder.
Lead Product(s): Risperidone
Therapeutic Area: Psychiatry/Psychology Product Name: LYN-005
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Lyndra Therapeutics
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 02, 2024
Details:
Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA).
Lead Product(s): Deuruxolitinib
Therapeutic Area: Dermatology Product Name: CTP-543
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Aclaris Therapeutics
Deal Size: Undisclosed Upfront Cash: $15.0 million
Deal Type: Licensing Agreement December 05, 2023
Details:
CDSCO has approved Silodosin (selective alpha1A-adrenergic receptor antagonist) + Tadalafil (PDE5 inhibitor), a fixed dose combination for the treatment of benign prostatic hyperplasia.
Lead Product(s): Silodosin,Tadalafil
Therapeutic Area: Urology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
